Jayasinghe Sanjay, Sheridan Sarah, Macartney Kristine
National Centre for Immunisation Research and Surveillance, Kids Research, The Children's Hospital at Westmead, Sydney.
Discipline of Child and Adolescent Health, Faculty of Medicine and Health, University of Sydney.
Aust Prescr. 2020 Feb;43(1):2-6. doi: 10.18773/austprescr.2020.001. Epub 2020 Feb 3.
Acute herpes zoster and associated postherpetic neuralgia is caused by reactivation of latent varicella zoster virus. It can be debilitating for older adults and interfere with activities of daily living A live, attenuated single-dose vaccine, that protects against both acute herpes zoster and postherpetic neuralgia, is available for free to all Australians aged 70 years, and in a catch-up program for those aged 71–79 years The vaccine is contraindicated in people who are immunocompromised, but can be considered in those who are receiving low doses of selected disease-modifying antirheumatic drugs Records of the Australian Immunisation Register suggest that only a third of 70 year olds received the vaccine in the first year-and-a-half of the program. This is likely an underestimation, but emphasises the importance of ensuring the vaccine is offered to all eligible patients and that vaccination is recorded on the Register A non-live recombinant herpes zoster vaccine has recently been developed which is more efficacious than the live vaccine in clinical trials. It is registered in Australia but not currently available
急性带状疱疹及相关的带状疱疹后神经痛是由潜伏的水痘-带状疱疹病毒重新激活引起的。它会使老年人身体衰弱,并干扰日常生活活动。一种预防急性带状疱疹和带状疱疹后神经痛的减毒活单剂量疫苗,可供所有70岁的澳大利亚人免费接种,71至79岁的人群可通过补种计划接种。该疫苗对免疫功能低下者禁用,但对于正在接受低剂量特定改善病情抗风湿药物治疗的患者可考虑使用。澳大利亚免疫登记册的记录显示,在该计划实施的头一年半时间里,只有三分之一的70岁老人接种了疫苗。这可能是低估,但强调了确保向所有符合条件的患者提供疫苗并将接种情况记录在登记册上的重要性。最近研发出一种非活性重组带状疱疹疫苗,在临床试验中比活性疫苗更有效。它已在澳大利亚注册,但目前尚未上市。